Skip to content

Study · Observational study · n = 46 · 2007

6 results

Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation.

Ji SM, Li LS, Sun QQ, Chen JS, Sha GZ, Liu ZH

Transplantation proceedings1 Jan 2007Cited by 19 (Europe PMC)

PMID17275486 (opens in a new tab)DOI10.1016/j.transproceed.2006.10.005 (opens in a new tab)PepBankPUB-17275486
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In renal transplant recipients with cytomegalovirus infection and acute respiratory distress syndrome, the rescue success rate was higher with thymosin alpha1 than in controls (78.1% vs 50.0%).

    In plain wordsIn transplant patients with a severe virus lung infection, more patients given thymosin alpha1 were rescued than patients in the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseRescue success rate
    Study

    n = 46

    Comparator
    Control group (rescue therapy without thymosin alpha1)
    Outcome group
    Mortality · Infection
    Studied dose
    1.6 mg every other day or every day · subcutaneousAs given in this study (human).

    Measurements

    Rescue success rate
    78.1%
    Zadaxin group
    Rescue success rate
    50%
    control group

    Source sentences

    Summary
    The rescue success rate was significantly higher in the Zadaxin than in the control group (78.1% vs 50.0%) while the death rate was greatly reduced (21.9% vs 50%).
    2 context sentences
    Summary · context
    The patients were divided into the thymosin alpha1 group (Zadaxin group, n = 32) and the control group (n = 14).
    Summary · context
    In addition, patients in the Zadaxin group received thymosin alpha1, (1.6 mg) subcutaneously every other day or every day.
  2. 02HumanObservational studyEfficacy outcome

    In renal transplant recipients with cytomegalovirus infection and acute respiratory distress syndrome, the death rate was lower with thymosin alpha1 than in controls (21.9% vs 50%).

    In plain wordsIn transplant patients with a severe virus lung infection, fewer patients given thymosin alpha1 died than patients in the control group.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDeath rate
    Study

    n = 46

    Comparator
    Control group (rescue therapy without thymosin alpha1)
    Outcome group
    Mortality · Infection
    Studied dose
    1.6 mg every other day or every day · subcutaneousAs given in this study (human).

    Measurements

    Death rate
    21.9%
    Zadaxin group
    Death rate
    50%
    control group

    Source sentences

    Summary
    The rescue success rate was significantly higher in the Zadaxin than in the control group (78.1% vs 50.0%) while the death rate was greatly reduced (21.9% vs 50%).
    2 context sentences
    Summary · context
    The patients were divided into the thymosin alpha1 group (Zadaxin group, n = 32) and the control group (n = 14).
    Summary · context
    In addition, patients in the Zadaxin group received thymosin alpha1, (1.6 mg) subcutaneously every other day or every day.
  3. 03HumanObservational studyEfficacy outcome

    In the thymosin alpha1 group, the CD4+ lymphocyte level rose significantly by day 14.

    In plain wordsIn transplant patients given thymosin alpha1, CD4 immune cell levels rose by day 14.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+ lymphocyte level at day 14
    Study

    n = 32

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg every other day or every day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the Zadaxin group, the CD4(+) lymphocyte level was significantly increased on day 14
    2 context sentences
    Summary · context
    The patients were divided into the thymosin alpha1 group (Zadaxin group, n = 32) and the control group (n = 14).
    Summary · context
    In addition, patients in the Zadaxin group received thymosin alpha1, (1.6 mg) subcutaneously every other day or every day.
  4. 04HumanObservational studyEfficacy outcome

    In the thymosin alpha1 group, the ratio of CD4+ to CD8+ T-lymphocyte subsets also rose significantly.

    In plain wordsIn transplant patients given thymosin alpha1, the balance of CD4 to CD8 immune cells also rose.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+/CD8+ T-lymphocyte ratio
    Study

    n = 32

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg every other day or every day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the Zadaxin group, the CD4(+) lymphocyte level was significantly increased on day 14; so was the ratio of CD4(+) and CD8(+) T-lymphocyte subsets.
    2 context sentences
    Summary · context
    The patients were divided into the thymosin alpha1 group (Zadaxin group, n = 32) and the control group (n = 14).
    Summary · context
    In addition, patients in the Zadaxin group received thymosin alpha1, (1.6 mg) subcutaneously every other day or every day.
  5. 05HumanObservational studyEfficacy outcome

    In the survival group, CD4+ lymphocyte counts were significantly higher on days 7, 14 and 21 than at admission.

    In plain wordsIn patients who survived, CD4 immune cell counts were higher on days 7, 14 and 21 than at admission.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+ lymphocyte count in survivors, days 7, 14 and 21
    Study

    n: not reported in source

    Comparator
    Admission values
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg every other day or every day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the survival group, CD4(+) and CD8(+) lymphocyte cell counts were significantly increased on days 7, 14, and 21 compared with admission.
    2 context sentences
    Summary · context
    The patients were divided into the thymosin alpha1 group (Zadaxin group, n = 32) and the control group (n = 14).
    Summary · context
    In addition, patients in the Zadaxin group received thymosin alpha1, (1.6 mg) subcutaneously every other day or every day.
  6. 06HumanObservational studyEfficacy outcome

    In the survival group, CD8+ lymphocyte counts were significantly higher on days 7, 14 and 21 than at admission.

    In plain wordsIn patients who survived, CD8 immune cell counts were higher on days 7, 14 and 21 than at admission.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD8+ lymphocyte count in survivors, days 7, 14 and 21
    Study

    n: not reported in source

    Comparator
    Admission values
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.6 mg every other day or every day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the survival group, CD4(+) and CD8(+) lymphocyte cell counts were significantly increased on days 7, 14, and 21 compared with admission.
    2 context sentences
    Summary · context
    The patients were divided into the thymosin alpha1 group (Zadaxin group, n = 32) and the control group (n = 14).
    Summary · context
    In addition, patients in the Zadaxin group received thymosin alpha1, (1.6 mg) subcutaneously every other day or every day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.